|
Activity Number:
|
473
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Wednesday, August 9, 2006 : 2:00 PM to 3:50 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #307536 |
|
Title:
|
Identifying Patients with Newly Diagnosed; Histologically Proven; Untreated; Symptomatic Stage I, II, or III Myeloma Who May Benefit from Dexamethasone
|
|
Author(s):
|
Keyue Ding*+
|
|
Companies:
|
Queen's University
|
|
Address:
|
10 Stuart Street, Kingston, ON, K7L 3N6, Canada
|
|
Keywords:
|
bump-hunting method ; clinical trial
|
|
Abstract:
|
Oncology Clinical Trials usually evaluate the efficacy of a new treatment by comparing the overall survival between all patients who are randomly assigned to the new treatment and those assigned to a standard/placebo treatment. But patients may react to the new treatment differently, some patients get significant benefit, some get less, while some may even be harmed by it. NCIC CTG trial of MY7, which investigate whether the combination of Melphalan and Dexamethasone (MD) is superior to the standard treatment of Melphalan and Prednisone (MP), showed that MD does not differ from MP in overall survival for study population. We undertake an exploratory analysis, using newly developed bump-hunting method, and find that male patients with ECOG performance of 0 or age of less than 60 were significantly benefit from MD, while female patients may be harmed by it.
|
- The address information is for the authors that have a + after their name.
- Authors who are presenting talks have a * after their name.
Back to the full JSM 2006 program |
